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A negative role for phosphoinositide 3-kinase in T-cell antigen
receptor function
Karin Reif, Susan Lucas and Doreen Cantrell
Background: A delicate balance between positive and negative regulatory
mechanisms during T-cell activation determines the specificity and magnitude of
an immune response. Phosphoinositide 3-kinase (PI 3-kinase) is activated by a
diverse set of receptors that determine T-cell function, including the T-cell
antigen receptor (TCR), the costimulatory receptor CD28, and negative
regulators of T-cell activation such as CTLA-4. PI 3-kinase is also regulated by
the haematopoietic cytokines that determine T-cell differentiation and lymphocyte
proliferation. PI 3-kinase can thus dynamically influence the outcome of the
immune reactions at various stages. In this study, we investigated the importance
of PI 3-kinase in TCR-directed T-cell activation using activated or inhibitory
versions of PI 3-kinase.
Results: Certain aspects of TCR responses such as the induction of
transcriptional activity of AP1 and serum response factor were not affected by
expression of the mutant forms of PI 3-kinase. We found, however, that PI 
3-kinase profoundly influenced the transactivation capacity of ‘nuclear factor of
activated T cells’ (NF-AT) elicited by the TCR: expression of an activated form of
PI 3-kinase inhibited TCR-mediated NF-AT responses, whereas expression of a
dominant negative mutant of PI 3-kinase potently enhanced TCR-controlled 
NF-AT induction. These effects of PI 3-kinase were not mediated by previously
identified PI 3-kinase effectors, such as protein kinase B, a positive regulator of
PI 3-kinase, or the GTPase Rac, and are therefore likely to involve a novel, as yet
unknown, effector molecule.
Conclusions: Our results establish that PI 3-kinase can both positively and
negatively regulate T-cell function, and uncover a previously unrecognized
function for PI 3-kinase in T cells as a selective negative regulator of TCR-
signalling events and therefore as a determinant of T-cell homeostasis.
Background
During T-cell activation, both positive and negative regula-
tory signalling cascades are vital for a balanced immune
response and immune homeostasis. T-cell activation is
orchestrated by the T-cell antigen receptor (TCR) and a
plethora of accessory molecules such as integrins, the tyro-
sine phosphatase CD45, the coreceptors CD4 and CD8,
and the costimulatory receptor CD28 [1–6]. These regula-
tory receptors thus determine the outcome of TCR engage-
ment by modulating TCR function and influencing the
thresholds of TCR occupancy required to initiate a T-cell
immune reaction.
Phosphoinositide 3-kinase (PI 3-kinase) is activated
during T-cell activation but its function in T cells is as yet
poorly understood [7,8]. PI 3-kinase comprises a regula-
tory p85 subunit and a catalytic p110 subunit which phos-
phorylates phosphatidylinositol 4,5-bisphosphate gener-
ating phosphatidylinositol 3,4,5-triphosphate (PI(3,4,5)P3)
[9,10]. Elevation of cellular levels of PI(3,4,5)P3 correlates
with PI 3-kinase action. Studies of PI 3-kinase activation
in T cells established that the TCR and CD28 can act in
concert to give a substantial rise in PI(3,4,5)P3 levels [11].
Intriguingly, PI 3-kinase is also associated with inhibitory
receptors such as CTLA-4 [12,13] or CD5 [14,15]. More-
over, PI 3-kinase activity is regulated by cytokines such as
IL-2/IL-4 which have a critical role in downregulating
immune hyperactivity [16]. It is thus clear that receptors
that activate PI 3-kinase can have major functions as nega-
tive regulators of the immune system.
Signal transduction events from the TCR are subject to
important autoregulatory and pararegulatory negative-
feedback control mechanisms: it is increasingly recognized
that receptors on T cells such as CTLA-4, inhibitory
MHC class I molecules and cytokine receptors can gener-
ate terminating signals, which are extremely important in
immune homeostasis [16–20]. There is only a primitive
understanding of the effector molecules that downmodu-
late TCR signal transduction, particularly in the context of
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negative-feedback mechanisms generated by the TCR
itself. As PI 3-kinase can cause pleiotropic function, it
could be critical for defining and revising the biological
responses from the TCR by eliciting negative signals.
We have employed genetic approaches using activated or
inhibitory mutants of PI 3-kinase to analyze the normal
cellular functions of the enzyme in T-cell activation
governed by the TCR. We examined the importance of PI
3-kinase in TCR-induced transcription factor responses
because transcription factors coordinate and implement
various activating or inhibitory input messages and are
ultimately responsible for fine-tuning the genetic
program. Here, we report that signals downstream from PI
3-kinase impair TCR-controlled transcription from the
NF-AT (‘nuclear factor of activated T cells’) response
element, whereas these signals do not interfere with the
signalling pathways that lead to gene transcription medi-
ated by AP1 or serum response factor (SRF). We show
that the serine/threonine protein kinase B (PKB; also
termed c-Akt) is activated by PI 3-kinase, but that active
PKB cannot substitute for active PI 3-kinase in the aboli-
tion of TCR-triggered transactivation by NF-AT. More-
over, a putative effector of PI 3-kinase action, the GTPase
Rac, does not appear to mediate the negative regulatory
effect of PI 3-kinase on NF-AT response elements. It is
therefore likely that an as yet unknown effector protein
controls the inhibitory action of PI 3-kinase on regulation
by NF-AT. Finally, we demonstrate that abrogation of
endogenous PI 3-kinase activity by expression of
inhibitory mutants of PI 3-kinase enhances TCR-induced
NF-AT transactivational activity. These results reveal that
PI 3-kinase can induce negative regulatory signals in T
cells and thus implicate PI 3-kinase as a selective modula-
tor of the genetic program initiated by TCR engagement.
Results
PI 3-kinase signals block TCR-induced transcription from
NF-AT response elements
Immediate responses to TCR triggering include the acti-
vation of transcription factors such as AP1, SRF and NF-
AT [21] which are ultimately important for cytokine gene
expression. Here, we have analyzed the consequences of
PI 3-kinase activation on transcription-factor regulation
by the TCR. The Jurkat T-cell line was transfected with
reporter genes responsive to different transcription factors
together with a constitutively active form of PI 3-kinase,
rCD2p110, comprising the extracellular and transmem-
brane domains of the rat CD2 (rCD2) cell surface antigen
fused to the amino-terminal domain of the p110a cat-
alytic subunit of PI 3-kinase [22]. As controls, cells were
similarly transfected with rCD2p110-R/P, a chimera
mutated at position 1130 thus catalytically inactivating
the kinase activity of the fusion protein [22]; rCD2p85, a
chimera comprising the rCD2 extracellular and trans-
membrane domains linked to the amino terminus of the
p85a regulatory subunit of PI 3-kinase [22]; and wild-
type rCD2. Expression of the rCD2-PI 3-kinase chimeras
was confirmed by flow cytometry (Fig. 1a). 
The induction of the transcription factor NF-AT by trig-
gering of the TCR or by the combined action of calcium
ionophore and phorbol ester (phorbol 12,13-dibutyrate;
PdBu) was studied. TCR induction of NF-AT was com-
pletely abrogated by expression of the activated PI 3-
kinase chimera, rCD2p110 (Fig. 1b). The repressive effect
of the active PI 3-kinase on NF-AT induction was selec-
tive because only TCR responses were prevented and
those of calcium ionophore and phorbol ester were unaf-
fected (Fig. 1c). TCR induction of NF-AT still occurred
in the presence of wild-type rCD2, ‘kinase-dead’
rCD2p110-R/P or rCD2p85 (Fig. 1b,c), showing that the
inhibitory effect of rCD2p110 on TCR/NF-AT responses
requires the lipid kinase activity of PI 3-kinase [22]. 
It was noted that expression of rCD2p85 could induce a
low level of NF-AT activity in the absence of stimulation.
We have observed previously that rCD2p85 acts as a mod-
erate inhibitory mutant of PI 3-kinase signalling pathways,
and this could explain the potentiating effect of rCD2p85
on NF-AT transcriptional activity (see Fig. 5). Signalling
pathways are initiated and modulated differentially in
divergent cell types, therefore the magnitude or quality of
a response is dependent upon cell context. We examined
the effects of the constitutively active PI 3-kinase on
TCR/NF-AT responses in the murine T-cell line EL4.
The data in Figure 1d show that TCR-mediated induction
of NF-AT was also suppressed in EL4 cells expressing the
activated rCD2p110 chimera; however, suppression was
not as complete as in Jurkat cells. This incomplete inhibi-
tion might occur because EL4 cells exhibit partial consti-
tutive activation of calcium/calcineurin signalling
pathways [23], which is one of the crucial signals required
for NF-AT regulation [24].
PI 3-kinase signals do not impair TCR-mediated induction
of AP1- or SRF-activated gene transcription
We next explored the role of PI 3-kinase signals on TCR-
mediated induction of the transcriptional activity of the 
c-fos serum response element (SRE) or AP1-driven
enhancer elements which are both central to the regula-
tion of immediate early genes. Activation at the SRE is
mediated by p21Ras/Raf/Erk (MAP kinase) pathways that
can be initiated in T cells by triggering of the TCR or by
phorbol ester (Fig. 2a). Expression of rCD2p110 had no
stimulatory effect on SRE activity but more importantly, it
did not compromise induction of SRE activity by TCR
cross-linking or treatment with phorbol ester. The tran-
scriptional activity of AP1 complexes induced by trigger-
ing of the TCR or treatment with phorbol ester plus
ionomycin was also unaffected by coexpression of
rCD2p110 (Fig. 2b). Expression of a constitutively active
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PI 3-kinase therefore has a selective modulatory effect on
the repertoire of transcription factor pathways activated by
the TCR: signals downstream of PI 3-kinase negatively
regulate the TCR signalling pathways that lead to NF-
AT-mediated transactivation but do not affect the TCR-
mediated induction of SRE and AP1-responsive elements.
PKB is stimulated by PI 3-kinase but does not inhibit
transactivation by NF-AT
PI 3-kinase signals are able to activate the serine/threonine
kinase PKB in fibroblasts [25,26]. This PI 3-kinase pathway
is important in regulating cell-survival responses in fibrob-
lasts and neuronal cells [27,28]. The negative effects of
active PI 3-kinase on TCR-mediated NF-AT responses
and its lack of effect on TCR-induced SRE and AP1 activa-
tion prompted us to examine the effects of rCD2p110 on
PKB activity in Jurkat cells. TCR triggering led to an
increase in PKB activity (Fig. 3a). Moreover, expression of
the membrane-localized PI 3-kinase, rCD2p110, was suffi-
cient to stimulate PKB activity to a level comparable to that
initiated by triggering of the TCR/CD3 complex (Fig. 3a).
PI 3-kinase action thus does not completely antagonize sig-
nalling from the TCR but can also positively regulate proxi-
mal TCR signal transduction events. We next investigated
whether PKB was involved in transmitting the inhibitory
effects of PI 3-kinase on TCR signalling. Expression of a
constitutively active PKB, gagPKB, did not mimic the
effect of active PI 3-kinase in the abrogation of TCR-medi-
ated NF-AT induction (Fig. 3b). PKB is thus not a candi-
date for mediating the inhibitory effect of PI 3-kinase on
TCR signalling.
Expression of V12Rac does not abrogate transactivation by
NF-AT but does induce SRF and AP-1 activity
We have shown recently that the active PI 3-kinase,
rCD2p110, can initiate signalling pathways mediated by the
GTPase Rac that lead to actin cytoskeleton rearrangements
in fibroblasts [22]. Rac can deliver signals for transcriptional
activation including stimulation of stress- activated protein
kinases [29–31]. We tested the possibility that Rac might
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PI 3-kinase functions as a negative regulator of TCR-mediated NF-AT
induction. (a) Flow cytometry of Jurkat T cells transiently transfected
with either rCD2, rCD2p85, rCD2p110, or rCD2p110-R/P expression
vectors (30 mg plasmid DNA) and stained with the anti-rCD2 Ox34
monoclonal antibody followed by fluorescein-conjugated rabbit anti-
mouse IgG (black line). As control, each population of transfected cells
was incubated with anti-mouse IgG as the primary antibody (dotted
line). (b,c) Jurkat cells or (d) EL4 cells were transfected with the NF-
AT.CAT reporter plasmid together with empty vector or plasmids
encoding rCD2p110, rCD2p110-R/P, rCD2p85, or rCD2 as
indicated. Cells were either left untreated (Control) or stimulated with
(b) anti-CD3 monoclonal antibody UCHT-1, (c) PdBu and ionomycin
(Iono), or (d) plate-bound anti-CD3 monoclonal antibody 2C11 for
(b,c) 13 h or (d) 16 h and then assayed for CAT activity. The CAT
activity is presented as percentage conversion. The data are from a
representative experiment, and in (d), two experiments are shown.
Similar results were obtained in seven (b,c) or three (d) more
experiments.
mediate the effects of PI 3-kinase on NF-AT activity.
Expression of constitutively active Rac, V12Rac, did not
substitute for PI 3-kinase in the inhibition of TCR-medi-
ated NF-AT responses (Fig. 4a). Moreover, V12Rac expres-
sion stimulated transcription regulated by SRF (Fig. 4b)
and AP1 (Fig. 4c), as did expression of Dbl (Fig. 4b,c), a
guanine nucleotide exchange factor for Rho family
GTPases that activates endogenous Rac and Rho [32].
Expression of rCD2p110 failed to elicit transcriptional
activity from the SRE or from AP1 elements indicating that
signals from PI 3-kinase do not apparently initiate Rac-
mediated transcription-factor pathways in T cells. In
addition, previous studies have shown that expression of an
inhibitory Rac mutant, N17Rac, suppresses rather than
potentiates TCR-induced NF-AT signal transduction
cascades [33]. These data demonstrate that effector path-
ways distinct from PKB- or Rac-governed signalling
cascades must mediate the effects of PI 3-kinase on TCR
function.
Expression of inhibitory mutants of PI 3-kinase enhances
TCR-induced NF-AT responses
It has been known for some time that TCR activation of
NF-AT is transient and subject to as yet uncharacterized
negative-feedback regulation [34–36]. The inhibitory
effects of active PI 3-kinase on TCR-mediated trans-
activation by NF-AT coupled with the fact that the TCR
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Figure 3
PKB is activated by PI 3-kinase but PKB does not mediate PI 3-kinase
regulatory effects on TCR-triggered NF-AT induction. (a) Jurkat cells
were cotransfected with HA–PKB plasmids and vector plasmid (empty)
or plasmid encoding rCD2p110 as indicated. Cells were left untreated
or were stimulated with UCHT-1 for 5 min prior to lysis. HA–PKB activity
was analyzed in anti-HA tag immune-complex kinase assays using H2B
as a substrate. [32P]-phosphate incorporation into H2B (upper panel)
was visualized by autoradiography. Protein levels of HA–PKB present in
immune complexes were assessed in parallel by western blotting with
anti-PKB Rac-PK-CT antibodies (lower panel). (b) Jurkat cells were
transfected with the NF-AT.CAT reporter plasmid together with empty
vector or plasmids encoding rCD2p110, or gagPKB as indicated. Cells
were left untreated (Control) or stimulated for 14 h with UCHT-1 and
then assayed for CAT activity. The CAT activity is presented as
percentage conversion. The data are from a representative experiment.
Similar results were obtained in two (a, b) more experiments.
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Figure 2
Expression of active PI 3-kinase does not interfere with TCR-induced
transcriptional activity from the SRE or from AP1 elements. Jurkat cells
were transfected with (a) SRE.CAT or (b) AP1.CAT reporter plasmids
together with empty vector or plasmids encoding rCD2p110, or
rCD2p110-R/P as indicated. Cells were left untreated (Control) or
stimulated overnight with UCHT-1, PdBu, and PdBu plus ionomycin as
indicated and subsequently assayed for CAT activity. The CAT activity
is presented as percentage conversion. The data are from a
representative experiment. Similar results were obtained in four (a) or
three (b) more experiments.
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activates PI 3-kinase raise the possibility that PI 3-kinase
may elicit deactivation of TCR-provoked NF-AT
responses. To test this hypothesis, we examined the effect
of p85D, an inhibitory mutant of PI 3-kinase, on TCR-
mediated induction of NF-AT. The p85D mutant corre-
sponds to a p85 regulatory subunit lacking the binding site
for the p110 catalytic subunit and therefore prevents regu-
lation and recruitment of the active enzyme complex to the
plasma membrane [37]. Expression of p85D led to a small
but reproducible basal induction of NF-AT activity, and
strikingly synergized with TCR stimulation to induce NF-
AT transcriptional activity (Fig. 5a,b). In contrast, p85D
had no effect on TCR-mediated induction at the SRE in
parallel experiments (Fig. 5c). The potentiating effect of
p85D is consistent with the notion that PI 3-kinase signals
antagonize the TCR signals that initiate NF-AT transcrip-
tional activity.
Discussion
As a delicate balance between positive and negative
signals is obligatory for an immune response, it is impor-
tant to characterize the full spectrum of intracellular mole-
cules that integrate these input signals. Although
substantial progress has been made to delineate positive
events, much less is known about effectors that negatively
modulate or terminate T-cell activation. The data pre-
sented here reveal a previously unrecognized function for
PI 3-kinase as a selective negative regulator of TCR
responses. The importance of this negative signalling role
for PI 3-kinase is underscored by its selective mode of
action: PI 3-kinase signals are sufficient to stimulate PKB,
a serine/threonine kinase involved in the regulation of sur-
vival responses in several cell systems; in contrast, 
PI 3-kinase signals abolish TCR-controlled NF-AT trans-
activation but allow TCR-mediated induction of AP1 or
SRE. Interestingly, an active allele of PKB did not abro-
gate NF-AT activity triggered by the TCR, nor did
expression of an activated form of the GTPase Rac, a
second well characterized effector of PI 3-kinase, abolish
NF-AT activity. This finding implicates an as yet unchar-
acterized effector pathway as the mediator of PI 3-kinase
regulation of the TCR-induced NF-AT response (Fig. 6).
The transcriptional activation of NF-AT is complex
process that involves translocation of the cytosolic NF-AT
component from the cytoplasm to the nucleus, where it
associates with its nuclear component, which contains
Fos/Jun (AP-1) family members that facilitate the DNA-
binding ability and transcriptional activity of NF-AT [38].
The precise mechanism for NF-AT inhibition by PI 
3-kinase awaits analysis. However, NF-AT induction by
the TCR requires the coordinate action of signalling path-
ways mediated by the phosphatase calcineurin, the
GTPase p21Ras, and may involve the adaptor protein
SLP-76 and Vav [3,4]. PI 3-kinase could thus exert its reg-
ulatory effects on NF-AT induction at multiple sites.
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Figure 4
Expression of active V12Rac or Dbl does not mimic PI 3-kinase signals
on gene transcription. Jurkat cells were transfected with (a) NF-
AT.CAT, (b) SRE.CAT or (c) AP1.CAT reporter plasmids together with
empty vector or plasmids encoding rCD2p110, V12Rac, or Dbl as
indicated. Cells were left untreated (Control) or stimulated overnight
with UCHT-1, PdBu, or PdBu plus ionomycin as indicated and
subsequently assayed for CAT activity. The CAT activity is presented
as percentage conversion. The data are from a representative
experiment. Similar results were obtained in two (a), three (b) or four
(c) more experiments.
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Cytokine gene expression upon activation of T cells is a
transient phenomenon subject to critical negative-feedback
control. NF-AT family members govern the transcription
of a number of genes including those for the cytokines IL-
2, IL-3, and IL-4, and for CD40 ligand and Fas ligand
[38,39]. In this respect, it has been recognized for several
years that there are negative-feedback signalling mecha-
nisms for the TCR-mediated induction of NF-AT [34–36].
These downregulating mechanisms are likely to be respon-
sible for the transience of cytokine gene expression during
T-cell activation. The data presented in this paper,
showing the reciprocal effects of activated and inhibitory
mutants of PI 3-kinase on TCR-delivered NF-AT
responses, are consistent with a model in which PI 3-kinase
has a negative-feedback or modulatory role in the induction
of NF-AT activity by the TCR (Fig. 6). TCR triggering
itself activates PI 3-kinase and the inhibitory PI 3-kinase
signals described herein might act as a physiologically rele-
vant homeostatic control mechanism in TCR function that
temporally restricts cytokine production to a limited period
of T-cell activation. 
Moreover, TCR-induced cytokines, such as IL-2 and IL-4,
act as growth factors in autocrine loops to drive T cells
through the cell cycle [40,41]. These growth factors are
powerful activators of PI 3-kinase [42–44] and a PI 3-
kinase-mediated NF-AT inhibitory pathway would ensure
that cytokine production is restricted to cells that have not
yet received a signal to proliferate. There is little reason for
a cell that is committed to proliferate to continue to
produce growth-regulatory cytokines (Fig. 6). Intriguingly,
it has been reported that NF-ATp/NF-AT1-deficient mice
show enhanced immune responses [39,45], which suggests
that NF-AT family proteins are involved in downregulat-
ing immune responses. PI 3-kinase downregulation of NF-
AT function would thus not only terminate the positive
growth regulatory signals generated by NF-AT, but would
also modulate the negative feedback functions of NF-AT.
There could also be broader implications for the terminat-
ing effects of PI 3-kinase on TCR function described in
this study: molecules such as CTLA-4 that negatively reg-
ulate T-cell activation [17–19] also associate with PI 3-
kinase [12]. Previous studies have ascribed the negative
effects of CTLA-4 signalling to the association of this
receptor with the tyrosine phosphatase SHP-2 [46].
However, there is no direct evidence that SHP-2 acts to
downregulate T-cell functions and it is noteworthy that
the p85 subunit of PI 3-kinase and SHP-2 interact with
the same phosphotyrosine motif, Tyr–Val–Lys–Met, in
the cytoplasmic domain of CTLA-4 via their SH2
domains [12,46]. PI 3-kinase could thus be a candidate for
mediating the negative effects of CTLA-4 on T-cell
action. In addition, PI 3-kinase could play a role in the
negative signalling pathways initiated by cytokines such
as IL-2 and IL-4. These issues are obviously complicated
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Figure 5
Expression of inhibitory alleles of PI 3-kinase potentiates TCR-mediated
NF-AT responses. Jurkat cells were transfected with (a, b) NF-AT.CAT or
(c) SRE.CAT, and cotransfected with empty vector or plasmids
encoding rCD2p110, rCD2p110-R/P or p85D as indicated. Cells were
left untreated (Control) or stimulated overnight with UCHT-1, or PdBu
plus ionomycin as indicated. The experiments shown in (b) and (c) were
performed in parallel. The CAT activity is presented as percentage
conversion. The data shown are from a representative experiment. Similar
results were obtained in four (a), two (b), or three (c) more experiments.
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by the fact that PI 3-kinase signals will undoubtedly be
influenced by other signalling pathways that are concur-
rently active within a cell. 
PI 3-kinase may thus have multiple roles and the precise
outcome of PI 3-kinase activation may be determined by
the number of different receptors that simultaneously
engage PI 3-kinase (quantitative modulation) (Fig. 6)
and/or the disparate effector pathways that are induced by
different receptors and can ‘cross-talk’ to PI 3-kinase effec-
tor cascades (qualitative modulation). In this context, it has
been well documented that different subpopulations of T
cells can vary dramatically in their cellular responsiveness
to signalling pathways. A clear example of this variability in
the context of ‘negative’ signalling is the induction of apop-
tosis by the death-inducing receptor Fas: cells expressing
Fas antigen can vary markedly in their susceptibility to
Fas-mediated apoptosis. In future studies, it will be of
interest to determine whether negative signals delivered by
PI 3-kinase resulting in inhibition of TCR-controlled NF-
AT induction, are ubiquitous with respect to function or
whether they are selective for certain T-cell populations.
As shown in this paper, PI 3-kinase signals will modulate
patterns of transcription factor activity and hence alter gene
expression regulated by the TCR in a specific manner,
rather than by generally disrupting TCR responses and
operating as a simple ‘off signal’ for the TCR. Modulation
of TCR function occurs at repeated points during T-cell
development and activation, for example, during the
processes of positive and negative selection in the thymus,
and in T-cell activation compared with T-cell anergy. The
data presented here identify PI 3-kinase as a determinant
of TCR-signalling thresholds for activation.
Conclusions
During T-cell activation and proliferation, PI 3-kinase is
activated by multiple receptors, such as the TCR, CD28,
IL-2R, IL-4R or CTLA-4, that can positively or nega-
tively regulate these processes. Hence, PI 3-kinase is
likely to have pleiotropic functions. In these studies, we
have defined one further function of PI 3-kinase in modu-
lating TCR-controlled transcription factor responses, in
that it selectively downregulates TCR-mediated induc-
tion of NF-AT transcriptional activity. This identifies PI
3-kinase as a determinant of negative signalling pathways
in T-cell activation and lymphocyte homeostasis.
Materials and methods
Plasmids
The plasmids for the following DNA constructs have been described
previously NF-AT.CAT (CAT, chloramphenicol acetyl transferase) and
AP1.CAT [33], SRE.CAT [47], HA-PKB and gagPKB [48], p85D [37],
V12Rac and Dbl [22]. The rCD2p85, rCD2p110 and rCD2p110-R/P
constructs, as well as the rCD2 cDNA have been described previously
[22] and were subcloned into the pEF-BOS expression vector.
Cell culture and transient transfections
Jurkat T cells (JHM1 2.2) [49] were maintained in RPMI 1640 supple-
mented with 10% foetal calf serum, 2 mM L-glutamine, 100 mg ml–1
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Figure 6
Schematic representation of the selective
negative role of PI 3-kinase in TCR signalling
leading to gene transcription. During T-cell
activation, PI 3-kinase is engaged by the TCR.
Other receptors that regulate PI 3-kinase
activity include CD28, CTLA-4, the IL-2R and
the IL-4R. TCR engagement delivers positive
signals to transcription factors such as AP1,
TCFs, SRF, and NF-AT, which ultimately
coordinate early gene transcription. This
transcription factor induction is subject to
negative-feedback mechanisms generated by
the TCR itself and by activation-dependent
receptors such as CTLA-4, the IL-2R and the
IL-4R. PI 3-kinase mediates positive aspects
of TCR signal transduction because it
stimulates PKB, an effector of PI 3-kinase that
can regulate cell survival. PI 3-kinase has the
potential to activate the GTPase Rac in order
to control cytoskeletal responses as has been
demonstrated in fibroblasts. PI 3-kinase also
delivers potent inhibitory signals and
negatively regulates NF-AT activity induced by
the TCR via an unknown effector protein. This
negative effect of PI 3-kinase is selective and
does not affect TCR-controlled transcription
from elements responsive to AP1 or
TCF/SRF.
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streptomycin, and 100 units ml–1 penicillin; EL4 murine thymoma cells
were also maintained in this medium but with the addition of 10 mM b-
mercaptoethanol [50]. Jurkat and EL4 T cells were transfected by elec-
troporation with 20–40 mg plasmid DNA. Amounts of plasmid DNA
were kept constant per cuvette by adding vector plasmid. Jurkat cells
(1.0–1.5 × 107 cells in 0.5 ml) were pulsed at 310 V and 960 mF. EL4
cells (1.0–1.5 × 108 cells in 0.29 ml) were pulsed at 250 V and
960 mF. The following amounts of plasmid were used unless indicated
otherwise: 15 mg of the following plasmids: pEF-empty, pEF-
rCD2p110, pEF-rCD2p110-R/P, pEF-rCD2p85, pEF-rCD2, or pSG5-
gagPKB; 10 mg of the following plasmids: pSG5-HA-PKB,
pcDSRa-p85D, pEF-V12Rac, pCMV-Dbl; 15 mg of NF-AT.CAT, 5 mg
of SRE.CAT and 2 mg of AP1.CAT. For gene reporter assays, cells
were stimulated 3 h to 6 h after transfection. Inductions were as
follows, unless indicated otherwise: 50 ng ml–1 phorbol 12,13 dibu-
tyrate (PdBu; Calbiochem), 500 ng ml–1 ionomycin (Ca2+ salt; Cal-
biochem). TCR crosslinking was achieved by stimulating Jurkat cells
with 5 mg ml–1 of the human CD3 antibody UCHT1 or by stimulating
EL4 cells with 10 mg ml–1 plate-bound murine CD3 antibody 2C11.
Immunofluorescence staining and flow cytometry
Cells transfected with rCD2 chimeras were subjected to immunofluo-
rescent staining and flow cytometry using 0.6 mg ml–1 Ox34 mono-
clonal antibody, and for control staining mouse IgG (Sigma), followed
by fluorescein isothiocyanate-conjugated rabbit anti-mouse IgG
(DAKO) using standard protocols.
Gene expression analysis
Cells were harvested and lysed in 200 ml lysis buffer (0.65% NP40,
10 mM Tris pH 8, 1 mM EDTA, 150 mM NaCl) 14–16 h after induc-
tions. Gene expression assays were carried out essentially as
described [33] except that the following assay conditions were used:
180 mM Tris pH 8, 7.3 mM [14C]acetyl coenzyme A (0.05 mCi),
0.174 mM acetyl coenzyme A, 1.74 mM chloramphenicol. The CAT
activity is presented as percentage conversion.
PKB kinase assays
Jurkat cells were stimulated with 5 mg ml–1 UCHT-1 monoclonal anti-
body and lysed (120 mM NaCl, 50 mM Hepes pH 7.4, 10 mM NaF,
1 mM EDTA, 40 mM b-glycerophosphate pH 7.5, 1% NP40, 0.1 mM
PMSF, 0.1 mM Na3VO4) 16 h after transfection. Postnuclear cell
extracts corresponding to 1 × 106 live cell equivalents were incubated
with 2 mg 12CA5 anti-haemagglutinin (HA) monoclonal antibody
(Boehringer Mannheim). Immune complexes were precipitated with
protein G–Sepharose beads (Sigma). The immunoprecipitates were
washed twice in lysis buffer, twice in high salt wash buffer (500 mM
LiCl, 100 mM Tris pH 7.5, 1 mM EDTA pH 7.5) and once in PKB
assay buffer (50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM DTT). The
reaction was initiated by the addition of 15 ml PKB reaction buffer
containing 3 mCi g-[32P]ATP, 50 mM ATP, 7.3 mM MgCl2, 730 mM
DTT, 500 nM protein kinase inhibitor (Sigma), 40 mM Tris pH 7.5, and
2.5 mg histone 2B (H2B) (Boehringer Mannheim). After 30 min at
25°C, the reaction was terminated by adding reducing SDS–PAGE
sample buffer and boiling. Proteins were resolved by SDS–PAGE and
32P-labelled H2B proteins were detected by autoradiography. The
levels of HA–PKB protein in each immunoprecipitate were assessed
by western blot analysis with a Rac-PK-CT antibody towards PKB
(Upstate Biotechnology Incorporated), using the ECL detection
system (Amersham).
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